Effects of Sildenafil in Resistant Hypertensives and Genetic Polymorphism
|ClinicalTrials.gov Identifier: NCT01392638|
Recruitment Status : Completed
First Posted : July 12, 2011
Last Update Posted : October 30, 2012
|Condition or disease||Intervention/treatment|
|Hypertension||Other: sugar pill Drug: sildenafil|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||120 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Influence of the Nitric Oxide Synthase T-786C Polymorphism on the Response to Acute Inhibition of Phosphodiesterase 5 in Resistant Hypertension|
|Study Start Date :||July 2010|
|Primary Completion Date :||July 2012|
|Study Completion Date :||September 2012|
Placebo Comparator: sugar pill
Intervention: sugar pill
Other: sugar pill
Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
Other Name: No brand name.
Active Comparator: sildenafil
Intervention: sildenafil citrate
Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
Other Name: Viagra, Pfizzer Lab., USA
- Cardiac Output, total peripheral resistance, mean arterial pressure [ Time Frame: Each 30 minutes ]Hemodynamic measures each 30 minutes
- Left ventricular diastolic function parameters, endothelial function [ Time Frame: Pre- and post-sildenafil accumulated doses ]Assessment of how hemodynamic changes determined by sildenafil would affect endothelial and left ventricular diastolic parameters.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01392638
|Laboratory of Cardiovascular Pharmacology - FCM - Unicamp|
|Campinas, SP, Brazil|
|Principal Investigator:||Heitor Moreno, PhD||Faculty of Medical Sciences - Unicamp|